Use of North America's first medically supervised safer injecting facility among HIV-positive injection drug users

AIDS Education and Prevention

Volumn 23, Issue 5, 2011, Pages 412-422

  Reddon, Hudson ^a   Wood, Evan ^a,b   Tyndall, Mark ^a,b   Lai, Calvin ^a   Hogg, Robert ^a,c   Montaner, Julio ^a,b   Kerr, Thomas ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DIAMORPHINE;

ADULT; ARTICLE; CANADA; DRUG USE; FEMALE; HEALTH CARE FACILITY; HIGH RISK POPULATION; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INJECTION DRUG USER; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NEEDLE; NURSING CARE; SUPERVISED INJECTING FACILITY;

ADULT; CANADA; DRUG USERS; FEMALE; HARM REDUCTION; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEEDLE-EXCHANGE PROGRAMS; PROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 80054799561     PISSN: 08999546     EISSN: None     Source Type: Journal    
DOI: 10.1521/aeap.2011.23.5.412     Document Type: Article

References (49)

1. Bourgois, P. (1998). The moral economies of homeless heroin addicts: Confronting ethnography, HIV risk, and everyday violence in San Francisco shooting encampments. Subst Use Misuse, 33(11), 2323-2351.
2. Burris, S., Blankenship, K. M., Donoghoe, M., Sherman, S., Vernick, J. S., Case, P. et al. (2004). Addressing the "risk environment" for injection drug users: the mysterious case of the missing cop. Milbank Q, 82(1), 125-156.
3. Choopanya, K., Des Jarlais, D. C., Vanichseni, S., Kitayaporn, D., Mock, P. A., Raktham, S. et al. (2002). Incarceration and risk for HIV infection among injection drug users in Bangkok. Journal of Acquired Immune Deficiency Syndromes, 29(1), 86-94.
4. Collins, C. B., Jr., Hearn, K. D., Whittier, D. N., Freeman, A., Stallworth, J. D., & Phields, M. (2010). Implementing packaged HIVprevention interventions for HIV-positive individuals: Considerations for clinic-based and community-based interventions. Public Health Rep, 125(Suppl. 1), 55-63.
5. Coyle, S. L., Needle, R. H., & Normand, J. (1998). Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Report, 113(Suppl. 1), 19-30.
6. Culhane, D. P., Gollub, E., Kuhn, R., & Shpaner, M. (2001). The co-occurrence of AIDS and homelessness: Results from the integration of administrative databases for AIDS surveillance and public shelter utilisation in Philadelphia. Journal of Epidemiological Community Health, 55(7), 515-520.
7. Darke, S., & Hall, W. (2003). Heroin overdose: Research and evidence-based intervention. Journal of Urban Health, 80(2), 189-200.
8. DeBeck, K., Small, W., Wood, E., Li, K., Montaner, J., & Kerr, T. (2009). Public injecting among a cohort of injecting drug users in Vancouver, Canada. Journal of Epidemiological Community Health, 63(1), 81-86.
9. Des Jarlais, D. C. (2000). Structural interventions to reduce HIV transmission among injecting drug users. AIDS, 14(Suppl. 1), S41-S46.
10. Des Jarlais, D. C., Perlis, T., Friedman, S. R., Deren, S., Chapman, T., Sotheran, J. L. et al. (1998). Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. American Journal of Public Health, 88(12), 1801-1806.
11. Dolan, K., Kimber, J., Fry, C., Fitzgerald, J., Mc-Donald, D., & Trautmann, F. (2000). Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug and Alcohol Review, 19, 337-346.
12. Ebright, J. R., & Pieper, B. (2002). Skin and soft tissue infections in injection drug users. Infectious Disease Clinic of North America, 16(3), 697-712.
13. Galea, S., Ahern, J., & Vlahov, D. (2003). Contextual determinants of drug use risk behavior: A theoretic framework. Journal of Urban Health, 80(4 Suppl 3), iii50-58.
14. Galea, S., & Vlahov, D. (2002). Social determinants and the health of drug users: Socioeconomic status, homelessness and incar ceration. Public Health Reports, 117(Suppl. 1), S135-145.
15. Hamers, F. F., & Downs, A. M. (2003). HIV in central and eastern Europe. The Lancet, 361(9362), 1035-1044.
16. Hedrich, D. (2004). European report on drug consumption rooms, European Monitoring Centre for Drugs and Drug Addiction. Luxembourg: Office for Official Publications of the European Communities.
17. Heimer, R., Bray, S., Burris, S., Khoshnood, K., & Blankenship, K. M. (2002). Structural interventions to improve opiate maintenance. International Journal of Drug Policy, 13(2), 103-111.
18. Kerr, T., Kimber, J., DeBeck, K., & Wood, E. (2007). The role of safer injection facilities in the response to HIV/AIDS among injection drug users. Current HIV/AIDS Reports, 4(4), 158-164.
19. Kerr, T., Small, D., Moore, D., & Wood, E. (2007). A micro-environmental intervention to reduce the harms associated with drug-related overdose: Evidence from the evaluation of Vancouver's safer injection facility. International Journal of Drug Policy, 18(1), 37-45.
20. Kerr, T., Wood, E., Grafstein, E., Ishada, T., Shannon, K., Lai, C. et al. (2004). High rates of primary care and emergency department use among injection drug users in Vancouver. Journal of Public Health, 27(1), 62-66.
21. Kimber, J., Dolan, K., van Beek, I., Hedrich, D., & Zurhold, H. (2003). Drug consumption facilities: An update since 2000. Drug and Alcohol Review, 22(2), 227-233.
22. Kimber, J., Dolan, K., & Wodak, A. (2005). Survey of drug consumption rooms: service delivery and perceived public health and amenity impact. Drug and Alcohol Rev, 24(1), 21-24.
23. Kresina, T. F., Bruce, R. D., & McCance-Katz, E.F. (2009). Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users. Current HIV Research, 7(4), 354-364.
24. Krüsi, A., Small, W., Wood, E., & Kerr, T. (2009). An integrated supervised injecting program within a care facility for HIV-positive individuals: A qualitative evaluation. AIDS Care, 21(5), 638-644.
25. Lloyd-Smith, E., Kerr, T., Hogg, R., Li, K., Montaner, J., & Wood, E. (2005). Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduction Journal, 2(1), 24.
26. Lyles, C. M., Kay, L. S., Crepaz, N., Herbst, J.H., Passin, W. F., Kim, A. S. et al. (2007). Best-evidence interventions: Findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000-2004. American Journal of Public Health, 97(1), 133-143.
27. Mathers, B. M., Degenhardt, L., Ali, H., Wiessing, L., Hickman, M., Mattick, R. P. et al. (2010). HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. The Lancet, 375(9719), 1014-1028.
28. Mathers, B. M., Degenhardt, L., Phillips, B., Wiessing, L., Hickman, M., Strathdee, S. A. et al. (2008). Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. The Lancet, 372(9651), 1733-1745.
29. McCoy, C. B., Lai, S., Metsch, L. R., Messiah, S.E., & Zhao, W. (2004). Injection drug use and crack cocaine smoking: Independent and dual risk behaviors for HIV infection. Annals of Epidemiology, 14(8), 535-542.
30. Mehta, S. H., Galai, N., Astemborski, J., Celentano, D. D., Strathdee, S. A., Vlahov, D. et al. (2006). HIV incidence among injection drug users in Baltimore, Maryland (1988-2004). Journal of Acquired Immune Deficiency Syndromes, 43(3), 368-372.
31. Milloy, M. J., Kerr, T., Mathias, R., Zhang, R., Montaner, J. S., Tyndall, M. et al. (2008). Non-fatal overdose among a cohort of active injection drug users recruited from a supervised injection facility. American Journal of Drug and Alcohol Abuse, 34(4), 499-509.
32. Milloy, M. J., Kerr, T., Tyndall, M., Montaner, J., & Wood, E. (2008). Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS One, 3(10), e3351.
33. O'Connor, P. G., Selwyn, P. A., & Schottenfeld, R.S. (1994). Medical care for injection-drug users with human immunodeficiency virus infection. New England Journal of Medicine, 331(7), 450-459.
34. Palepu, A., Tyndall, M. W., Leon, H., Muller, J., O'Shaughnessy, M. V., Schechter, M. T. et al. (2001). Hospital utilization and costs in a cohort of injection drug users. Canadian Medical Association Journal, 165(4), 415-420.
35. Patrick, D. M., Tyndall, M. W., Cornelisse, P. G., Li, K., Sherlock, C. H., Rekart, M. L. et al. (2001). Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ, 165(7), 889-895.
36. Rhodes, T. (2002). The "risk environment": a framework for understanding and reducing drug-related harm. International Journal of Drug Policy, 13(2), 85-94.
37. Rhodes, T., Kimber, J., Small, W., Fitzgerald, J., Kerr, T., Hickman, M. et al. (2006). Public injecting and the need for "safer envi ronment interventions" in the reduction of drug-related harm. Addiction, 101(10), 1384-1393.
38. Rhodes, T., Singer, M., Bourgois, P., Friedman, S.R., & Strathdee, S. A. (2005). The social structural production of HIV risk among injecting drug users. Social Science and Medicine, 61(5), 1026-1044.
39. Singer, M., Stopka, T., Siano, C., Springer, K., Barton, G., Khoshnood, K. et al. (2000). The social geography of AIDS and hepatitis risk: Qualitative approaches for assessing local differences in sterile-syringe access among injection drug users. American Journal of Public Health, 90(7), 1049-1056.
40. Small, W., Wood, E., Lloyd-Smith, E., Tyndall, M., & Kerr, T. (2008). Accessing care for injection-related infections through a medically supervised injecting facility: A qualitative study. Drug and Alcohol Dependency, 98(1-2), 159-162.
41. Stoltz, J. A., Wood, E., Small, W., Li, K., Tyndall, M., Montaner, J. et al. (2007). Changes in injecting practices associated with the use of a medically supervised safer injection facility. Journal of Public Health (Oxford), 29(1), 35-39.
42. Tyndall, M., Wood, E., Zhang, R., Lai, C., Montaner, J., & Kerr, T. (2006). HIV seroprevalence among participants at a supervised injection facility in Vancouver, Canada: Implications for prevention care and treatment. Harm Reduction Journal, 3(36), 36-41.
43. Tyndall, M. W., Currie, S., Spittal, P., Li, K., Wood, E., O'Shaughnessy, M. V. et al. (2003). Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS, 17(6), 887-893.
44. UNAIDS. (2006). Report on the global AIDS epidemic, Geneva, Switzerland: UNAIDS.
45. Wood, E., Kerr, T., Lloyd-Smith, E., Buchner, C, Marsh, DC., Montaner, J. et al. (2004). Methodology for evaluating Insite: Canada's first medically supervised safer injection facility for injection drug users. Harm Reduction Journal, 1(1), 9.
46. Wood, E., Montaner, J. S., Li, K., Zhang, R., Barney, L., Strathdee, S. A. et al. (2008). Burden of HIV infection among aboriginal injection drug users in Vancouver, British Columbia. American Journal of Public Health, 98(3), 515-519.
47. Wood, E., Montaner, J. S., Yip, B., Tyndall, M. W., Schechter, M. T., O'Shaughnessy M. V. et al. (2003). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. Canadian Medical Association Journal, 169(7), 656-661.
48. Wood, E., Tyndall, M. W., Qui, Z., Zhang, R., Montaner, J. S., & Kerr, T. (2006). Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility. American Journal of Public Health, 96(5), 770-773.
49. Young, D. M., Harris, H. W., Charlebois, E. D., Chambers, H., Campbell, A., Perdreau-Remington, F. et al. (2004). An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients. Archives of Surgery, 139(9), 947-953.